**Name of Journal: *World Journal of Orthopedics***

**Manuscript NO: 33239**

**Manuscript Type: Systematic Reviews**

**Systematic review of bone marrow stimulation for osteochondral lesion of talus - evaluation for level and quality of clinical studies**

Yasui Y *et al*. A review of BMS for osteochondral lesion of talus

**Youchi Yasui, Laura Ramponi, Dexter Seow, Eoghan T Hurley,Wataru Miyamoto,Yoshiharu Shimozono, John G Kennedy**

**Youichi Yasui**, Department of Orthopaedic Surgery, Teikyo University School of Medicine, Tokyo 173-8606, Japan

**Youichi Yasui, Laura Ramponi, Dexter Seow, Eoghan T Hurley, Wataru Miyamoto, Yoshiharu Shimozono, John G Kennedy,** Hospital for Special Surgery, New York, NY 10021, United States

**Laura Ramponi**, 2nd Rizzoli Orthopaedic Institute, 4.136 Bologna, Italy

**Dexter Seow**, **Eoghan T Hurley**, 2nd Royal College of Surgeons in Ireland, Dublin 2, Ireland

**Wataru Miyamoto**, Department of Orthopaedic Surgery, Teikyo University School of Medicine, Tokyo 173-8606, Japan

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** Kennedy JG is a consultant for Arteriocyte, Inc.; has received research support from the Ohnell Family Foundation, Mr. and Mrs. Michael J Levitt, and Arteriocyte Inc.; is a board member for the European Society of Sports Traumatology, Knee Surgery, and Arthroscopy, International Society for Cartilage Repair of the Ankle, American Orthopaedic Foot and Ankle Society Awards and Scholarships Committee, International Cartilage Repair Society finance board.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author “insert email”, who will provide a permanent, citable and open-access home for the dataset.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** **Youichi Yasui, MD,** Department of Orthopaedic Surgery, 2nd Teikyo University School of Medicine, 1-1 Kaga, 2-Chome, Itabashi-Ku, Tokyo 173-8606, Japan. youichi@med.teikyo-u.ac.jp

**Telephone:** +81-3-3964-4097

**Fax:** +81-3-5375-6864

**Received:** January 29, 2017

**Peer-review started:** February 13, 2017

**First decision:** May 10, 2017

**Revised:** July 29, 2017

**Accepted:** August 15, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To clarify the quality of the studies indicating lesion size and/or containment as prognostic indicators of bone marrow stimulation (BMS) for osteochondral lesions of the talus (OLT).

***MEHODS***

Two reviewers searched the PubMed/MEDLINE and EMBASE databases using specific terms on March 2015 in accordance with the Preferred Reporting Items for Systemic Reviews and Meta-Analyses guidelines. Predetermined variables were extracted for all the included studies. Level of evidence (LOE) was determined using previously published criteria by the *Journal of Bone and Joint Surgery* and methodological quality of evidence (MQOE) was evaluated using the Modified Coleman Methodology Score.

***RESULTS***

This review included 22 studies. Overall, 21 of the 22 (95.5%) included studies were level IV or level III evidences. The remaining study was a level II evidence. MQOE analysis revealed 14 of the 22 (63.6%) included studies having fair quality, 7 (31.8%) studies having poor quality and only 1 study having excellent quality.

***CONCLUSION***

The evidence supporting the use of lesion size and containment as prognostic indicators of BMS for OLTs has been shown to be of low quality.

**Key words:** Osteochondral lesion of talus; Arthroscopy; Bone marrow stimulation; Systematic review

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Bone marrow stimulation (BMS) is a reparative procedure for osteochondral lesions of the talus, promising approximately 85% success rates in the short- and mid-term. To date, the prognostic factors for BMS are lesion size and containment of the lesion. No other factors have been shown to be universal predictors. However, the level of evidence and methodological quality of evidence for clinical studies accompanying both the lesion sizes and containment are low. Overall, 95.5% of the studies included in the analysis are level IV or level III. No level I study was identified. The methodological qualities of the included studies were not strong. In particular, the scores of “primarily evaluates outcome criteria and recruitment rates” were low.

Yasui Y, Ramponi L, Seow D, Hurley ET,Miyamoto W,Shimozono Y, Kennedy JG. Systematic review of bone marrow stimulation for osteochondral lesion of talus - evaluation for level and quality of clinical studies. *World J Orthop* 2017; In press

**INTRODUCTION**

Bone marrow stimulation (BMS) is a reparative procedure for osteochondral lesions of the talus (OLT)[1]. The aim of this arthroscopic procedure is to stimulate mesenchymal stem cells (MSCs) to promote fibrous cartilage tissue by breaching the subchondral bone plate (SBP) using an awl or wire[1]. Several investigators have demonstrated good to excellent clinical outcomes in around 85% of patients, treated with BMS for OLT, for the short to medium term[2].

The main prognostic factor in the treatment of OLT has been regarded as the lesion size[1,3,4]. The maximum size for BMS treatment is generally accepted as less than 15 mm in diameter or 150 mm2 in area. Chuckpaiwong *et al*[4] found that smaller than 15 mm in diameter was the critical cut-off value to obtain a successful outcome following BMS. Choi *et al*[5] concluded that 150 mm2 is the critical defect area beyond clinical outcomes following BMS for OLT decreased significantly. However, a recent systematic review by Ramponi *et al*[6] showed the critical lesion size to be 107.4 mm2 in area and/or 10.2 mm in diameter, for BMS. Containment of the lesion has also been demonstrated as a universally accepted prognostic factor for good clinical outcomes following BMS for OLT[3,7].

Recently, level of evidence (LOE) and methodological quality of evidence (MQOE) have been used to assess relative value of outcomes reported in the clinical studies[8-11]. Despite the widespread clinical use of lesion size as a cut-off value for BMS in OLT, there has been no comprehensive assessment of LOE and QOE for clinical studies accompanying both the lesion size and clinical outcomes. The same can be said for the presence or absence of containment of OLT.

The purpose of this systematic review was to clarify the LOE and MQOE of for the published literature investigating clinical outcome following BMS for OLT, with special emphasis on studies investigating lesion size and containment as predictors.

**MATERIALS AND METHODS**

***Search strategy***

A systematic literature search of the PubMed/MEDLINE and EMBASE databases was performed in March 2015 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[12]. Each database was searched using the following key words, (microfracture OR microdrilling OR drilling OR drill OR bone marrow stimulation OR marrow stimulation OR BMS OR abrasion chondroplasty OR arthroscopy OR arthroscopic) AND (talus OR talar OR ankle) AND (cartilage OR osteochondritis dissecans OR chondral OR osteochondral OR transchondral OR osteochondral lesion OR OCL OR OCD).

Titles and abstracts were screened using specific inclusion and exclusion criteria. Full texts of potentially relevant studies were then reviewed. Citations and references of all articles and relevant studies were manually assessed. Studies were searched and independently assessed by two independent reviewers. Differences between reviewers were discussed together and resolved by consensus or if a persistent disagreement occurred, a senior author was consulted.

***Inclusion and exclusion criteria***

Currently BMS is defined as microfracture, drilling, or abrasion. The inclusion criteria of the current systematic review was the following: (1) therapeutic clinical studies evaluating both lesion size of OLT and outcomes in patients who underwent BMS; (2) all patients included had more than a 24 mo follow up; (3) published in a peer-review journal; (4) published in English; and (5) full text of studies available. Exclusion criteria was the following: (1) cadaveric studies; (2) animal studies; (3) case reports; (4) review articles; (5) technique articles; (6) articles with unseparated results if more than one technique is described; (7) inadequately surgical technique description; (8) use of scaffolds; and (9) errors in reported data.

***Data extraction and analysis***

Two independent reviewers performed data extraction for each study. If any discrepancy existed, the senior author evaluated all available data and a consensus was reached. Studies that included more than one surgical procedure or a subgroup of patients with different follow-up times were included in the data for analysis[13,14].

The primary outcome of current study was LOE and MQOE of included studies. LOE of each study was graded based on the previously published criteria[15]. MQOE was assessed using the Modified Coleman Methodology Score (MCMS) (Table 1)[6]. This score consists of 2 parts, Part A (primarily evaluates baseline study characteristics; 0-60) and Part B (primarily evaluates outcome criteria and recruitment rates; 0-40). According to Jakobsen’s CMS, the score of excellent studies are between 85 to 100 points; good studies 70 to 84 points, fair studies 55 to 69 points and poor studies scored under 55 points[9].

***Statistical analysis***

The statistical analysis was performed using a commercially available contemporary statistical software package (SAS 9.3; SAS Institute, Cary, NC). In CMMS, all obtained scores were adjusted to percentage (each score/total score), the adjusted scores of CMMS were compared between Part A and Part B to determine statistical significance. As a Shapiro-Wilk’s *W* test showed non-normal distributed data, the Mann-Whitney *U* test was performed for this. Additionally, the adjusted score of each parameter were compared to investigate any difference using the Kruskal-Wallis test and Steel-Dwass test for data obtained without standard Gaussian distribution.A *P*-value *<* 0.05 was considered statistically significant.

**RESULTS**

The flow diagram is shown in Figure 1. After full texts articles were assessed based on the inclusion/exclusion criteria. There were 22 clinical studies included in the current systematic review[3-5,7,13,16-32].

***Demographics***

Summary of the demographic data was shown in Table 2: 1.879 ankles were identified (931 males; 545 females)[3-5,7,13,16-32]. The mean lesion area was 111.9 mm2 and the mean diameter was 9.5 mm. The mean follow-up was 48.5 (range 24-146) mo.

***LOE***

Overall, 95.5% of the studies included were level IV[4,7,17,18,20,22,25-29,31] or level III[3,5,16,19,21,23,30,32]. No level I studies were included in the current review. Gobbi *et al*[13], was described as LOE I in the published journal, however, this study was re-assigned as LOE II (prospective cohort study). Table 2 shows information about LOE (Table 2).

***MQOE***

The mean MCMS was 57.5 ± 10.2 out of 100 points (range 38-89) (Table 3). Part A was 38.1 ± 8.1 (range 22-60; percentage: 63.5%) and Part B was 19.2 ± 5.5 (range 11-29; percentage: 48.0%), respectively. The adjusted MCMS of Part A were significantly higher than that of Part B (*P* < 0.05). In the part A, the adjusted MCMS of “Type of study” were significantly lower among all the parameters (*P* < 0.05). With regard to Part B, “Outcome criteria” had significantly higher scores compared with the others (*P* < 0.05). Of the 22 included studies, 14 studies (63.6%) were of fair quality[3-5,13,19,20,23-25,27,28,30-32], 7 (31.7%) of poor quality[7,16-18,22,26,28] and only 1 (4.5%) study[21].

**DISCUSSION**

The aim of this systematic review is to clarify LOE and MQOE of published literature on BMS for OLT. Twenty-two studies with 1.879 patients were included, however, no level I study was identified in the study cohort. The result demonstrated that most of the studies reported the lesion sizes and the containment of the lesion were graded as low LOE. The quality of evidence in these studies demonstrated an average MCMS of 57.5 out of 100 points and only 4.5% of included studies were graded as excellent, which suggests that the methodological quality of the included studies was weak. In addition, scores of Part B (primarily evaluates outcome criteria and recruitment rates) was marked significantly lower than Part A (primarily evaluates baseline study characteristics. This systematic review has revealed that studies with low LOE and weak MQOE have supported this paradigm despite lesion size and the containment of the lesion being a common criteria value for the indication for BMS in treating OLT.

Lesion size and the containment of the lesion are accepted prognostic factors to use when making a decision in operative treatment for OLT[3,7]. In general, lesion size with less than 15 mm in diameter or less than 150 mm2 are applied for BMS. It is also well known that a non-contained OLT have a worse outcome than a contained OLT[7]. However, this systematic review has revealed that most of these studies were of low LOE, and recently, several investigators evaluated the trend of LOE of published clinical studies in sport-related journals[33]. Unfortunately greater than 80% of studies in foot and ankle surgery remain to have low LOE despite increasing numbers of the LOE I and LOE II studies in the clinical sports medicine literature[9,10,33]. High-level clinical evidence can fundamentally provide adequate treatment for patients based on the principles of evidence-based medicine[34]. Additionally, Moher *et al*[35] described that non-blinded clinical studies without allocation concealment tended to describe an overestimated treatment effect than blinded clinical studies and well-designed blinded case control studies are required to establish prognostic factors in BMS for OLT.

The current systematic study revealed that the MQOE of the included 22 studies have been weak (Table 3)[9]. Of those clinical studies “Procedure for assessing outcomes” and “Description of subject selection process” in Part B (primarily evaluates outcome criteria and recruitment rates) were significantly low. These findings are consistent with the outcomes found by a recent systematic review that analyzed the outcome data following microfracture for OLT in 24 clinical studies[36]. The authors found that approximately half of included studies did not have a patient history or patient-reported outcome data, despite the presence of well described general demographics and study design. Additionally, clinical variables (48%) and imaging data (39%) has been the least reported in these studies. Poor methodological quality of the clinical study decreases the reliability of study’s outcomes[37]. However, caution should be taken when interrupting the outcomes of methodological quality. The methodological deficiencies have been reported using Coleman Methodological Score for tendinopathy[8,38], knee cartilage lesion[9], fracture[39], ligament injury[40-42] and OLT[43]. However, to our knowledge, the validity and reliability of this score for OLT is unknown. Nevertheless, we believe the outcome of the current study is important because the modification for MCMS in the current study could improve the validity and reliability of this score for OLT.

Several limitations of the current study exist mainly due to the inclusion criteria. Studies published in database other than MEDLINE and EMBASE were not included. Clinical studies not written in English were not evaluated. Nevertheless, this study does demonstrate important findings of that the LOE and QOE of published literature, on using BMS for OLT, are insufficient to produce any solid conclusion. A further limitation was that the current study focused only on the available clinical studies. As a result, the outcomes have addressed very little of the underlying mechanisms and intrinsic limitations of BMS for OLT. Currently, underlying biological aspects of cartilage regeneration has been well discussed due to low intrinsic activity of reparative cartilaginous tissue following BMS and potential ability of biological factors, although a recent systematic review has suggested a comprehensive assessment of the evidence behind the translation of basic science to the clinical practice[44,45]. Thus, the usefulnessof the outcomes from the current study depends essentially on critical appraisal of the literature on the clinical application.

In conclusion, lesion size and the containment of OLT is a commonly used prognostic parameter in the treatment of osteochondral lesion of the talus However, this systematic review has revealed that low levels of evidence and weak quality of evidence in clinical studies need to be improved before this paradigm can be fully supported.

**COMMENTS**

***Background***

Lesion sizes and containment are commonly used in the orthopaedic community to predict the clinical outcomes of bone marrow stimulation for osteochondral lesion of talus.

***Research frontiers***

The widespread use of lesion size and containment as prognostic indicators prompts a much-needed comprehensive assessment of the studies supporting this data.

***Innovations and breakthroughs***

The evidence supporting the use of lesion size and containment as prognostic indicators of bone marrow stimulation (BMS) for osteochondral lesion of the talus (OLTs) have been revealed in this study to be of low level of evidence (LOE) and of weak methodological quality of evidence. Future studies with more robust study designs are warranted should the current paradigm ever need to be fully supported.

***Applications***

This systematic review has revealed that low levels of evidence and weak quality of evidence in clinical studies need to be improved before this paradigm can be fully supported.

***Terminology***

BMS: Bone marrow stimulation; LOE: Level of evidence; MCMS: Modified Coleman Methodology Score; MQOE: Methodological quality of evidence; OLT: Osteochondral lesion of the talus.

***Peer-review***

This is a timely, objective, well-written, well-conducted systematic review of a topic relevant to the field of orthopaedics.

**REFERENCES**

1 **Murawski CD**, Kennedy JG. Operative treatment of osteochondral lesions of the talus. *J Bone Joint Surg Am* 2013; **95**: 1045-1054 [PMID: 23780543 DOI: 10.2106/JBJS.L.00773]

2 **Zengerink M**, Struijs PA, Tol JL, van Dijk CN. Treatment of osteochondral lesions of the talus: a systematic review. *Knee Surg Sports Traumatol Arthrosc* 2010; **18**: 238-246 [PMID: 19859695 DOI: 10.1007/s00167-009-0942-6]

3 **Choi WJ**, Choi GW, Kim JS, Lee JW. Prognostic significance of the containment and location of osteochondral lesions of the talus: independent adverse outcomes associated with uncontained lesions of the talar shoulder. *Am J Sports Med* 2013; **41**: 126-133 [PMID: 22859663 DOI: 10.1177/0363546512453302]

4 **Chuckpaiwong B**, Berkson EM, Theodore GH. Microfracture for osteochondral lesions of the ankle: outcome analysis and outcome predictors of 105 cases. *Arthroscopy* 2008; **24**: 106-112 [PMID: 18182210 DOI: 10.1016/j.arthro.2007.07.022]

5 **Choi WJ**, Park KK, Kim BS, Lee JW. Osteochondral lesion of the talus: is there a critical defect size for poor outcome? *Am J Sports Med* 2009; **37**: 1974-1980 [PMID: 19654429 DOI: 10.1177/0363546509335765]

6 **Ramponi L**, Yasui Y, Murawski CD, Ferkel RD, DiGiovanni CW, Kerkhoffs GMMJ, Calder JDF, Takao M, Vannini F, Choi WJ, Lee JW, Stone J, Kennedy JG. Lesion Size Is a Predictor of Clinical Outcomes After Bone Marrow Stimulation for Osteochondral Lesions of the Talus: A Systematic Review. *Am J Sports Med* 2017; **45**: 1698-1705 [PMID: 27852595]

7 **Cuttica DJ**, Smith WB, Hyer CF, Philbin TM, Berlet GC. Osteochondral lesions of the talus: predictors of clinical outcome. *Foot Ankle Int* 2011; **32**: 1045-1051 [PMID: 22338953]

8 **Coleman BD**, Khan KM, Maffulli N, Cook JL, Wark JD. Studies of surgical outcome after patellar tendinopathy: clinical significance of methodological deficiencies and guidelines for future studies. Victorian Institute of Sport Tendon Study Group. *Scand J Med Sci Sports* 2000; **10**: 2-11 [PMID: 10693606]

9 **Jakobsen RB**, Engebretsen L, Slauterbeck JR. An analysis of the quality of cartilage repair studies. *J Bone Joint Surg Am* 2005; **87**: 2232-2239 [PMID: 16203888 DOI: 10.2106/JBJS.D.02904]

10 **Barske HL**, Baumhauer J. Quality of research and level of evidence in foot and ankle publications. *Foot Ankle Int* 2012; **33**: 1-6 [PMID: 22381229 DOI: 10.3113/FAI.2012.0001]

11 **Zaidi R**, Abbassian A, Cro S, Guha A, Cullen N, Singh D, Goldberg A. Levels of evidence in foot and ankle surgery literature: progress from 2000 to 2010? *J Bone Joint Surg Am* 2012; **94**: e1121-e1110 [PMID: 22855001 DOI: 10.2106/JBJS.K.01453]

12 **Liberati A**, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; **339**: b2700 [PMID: 19622552 DOI: 10.1136/bmj.b2700]

13 **Gobbi A**, Francisco RA, Lubowitz JH, Allegra F, Canata G. Osteochondral lesions of the talus: randomized controlled trial comparing chondroplasty, microfracture, and osteochondral autograft transplantation. *Arthroscopy* 2006; **22**: 1085-1092 [PMID: 17027406 DOI: 10.1016/j.arthro.2006.05.016]

14 **Tao H**, Shang X, Lu R, Li H, Hua Y, Feng X, Chen S. Quantitative magnetic resonance imaging (MRI) evaluation of cartilage repair after microfracture (MF) treatment for adult unstable osteochondritis dissecans (OCD) in the ankle: correlations with clinical outcome. *Eur Radiol* 2014; **24**: 1758-1767 [PMID: 24816939 DOI: 10.1007/s00330-014-3196-8]

15 **Marx RG**, Wilson SM, Swiontkowski MF. Updating the assignment of levels of evidence. *J Bone Joint Surg Am* 2015; **97**: 1-2 [PMID: 25568387 DOI: 10.2106/JBJS.N.01112]

16 **Draper SD**, Fallat LM. Autogenous bone grafting for the treatment of talar dome lesions. *J Foot Ankle Surg* 2000; **39**: 15-23 [PMID: 10658946]

17 **Lee KB**, Bai LB, Chung JY, Seon JK. Arthroscopic microfracture for osteochondral lesions of the talus. *Knee Surg Sports Traumatol Arthrosc* 2010; **18**: 247-253 [PMID: 19779893 DOI: 10.1007/s00167-009-0914-x]

18 **Jung HG**, Carag JA, Park JY, Kim TH, Moon SG. Role of arthroscopic microfracture for cystic type osteochondral lesions of the talus with radiographic enhanced MRI support. *Knee Surg Sports Traumatol Arthrosc* 2011; **19**: 858-862 [PMID: 21318384 DOI: 10.1007/s00167-011-1411-6]

19 **Choi WJ**, Kim BS, Lee JW. Osteochondral lesion of the talus: could age be an indication for arthroscopic treatment? *Am J Sports Med* 2012; **40**: 419-424 [PMID: 21984689 DOI: 10.1177/0363546511423739]

20 **Kuni B**, Schmitt H, Chloridis D, Ludwig K. Clinical and MRI results after microfracture of osteochondral lesions of the talus. *Arch Orthop Trauma Surg* 2012; **132**: 1765-1771 [PMID: 22899211 DOI: 10.1007/s00402-012-1595-3]

21 **Lee DH**, Lee KB, Jung ST, Seon JK, Kim MS, Sung IH. Comparison of early versus delayed weightbearing outcomes after microfracture for small to midsized osteochondral lesions of the talus. *Am J Sports Med* 2012; **40**: 2023-2028 [PMID: 22879399 DOI: 10.1177/0363546512455316]

22 **Sallakh SE**. Arthroscopic debridement and microfracture for osteochondral lesions of the talus. *Current Orthopaedic Practice* 2012; **23**: 116-121 [DOI: 10.1097/YCO.0b013e318247c2fb]

23 **Angthong C**, Yoshimura I, Kanazawa K, Takeyama A, Hagio T, Ida T, Naito M. Critical three-dimensional factors affecting outcome in osteochondral lesion of the talus. *Knee Surg Sports Traumatol Arthrosc* 2013; **21**: 1418-1426 [PMID: 23328985 DOI: 10.1007/s00167-013-2364-8]

24 **Choi GW**, Choi WJ, Youn HK, Park YJ, Lee JW. Osteochondral lesions of the talus: are there any differences between osteochondral and chondral types? *Am J Sports Med* 2013; **41**: 504-510 [PMID: 23354117 DOI: 10.1177/0363546512472976]

25 **van Bergen CJ**, Kox LS, Maas M, Sierevelt IN, Kerkhoffs GM, van Dijk CN. Arthroscopic treatment of osteochondral defects of the talus: outcomes at eight to twenty years of follow-up. *J Bone Joint Surg Am* 2013; **95**: 519-525 [PMID: 23515986 DOI: 10.2106/JBJS.L.00675]

26 **Ventura A**, Terzaghi C, Legnani C, Borgo E. Treatment of post-traumatic osteochondral lesions of the talus: a four-step approach. *Knee Surg Sports Traumatol Arthrosc* 2013; **21**: 1245-1250 [PMID: 22572867 DOI: 10.1007/s00167-012-2028-0]

27 **Yoshimura I**, Kanazawa K, Takeyama A, Angthong C, Ida T, Hagio T, Hanada H, Naito M. Arthroscopic bone marrow stimulation techniques for osteochondral lesions of the talus: prognostic factors for small lesions. *Am J Sports Med* 2013; **41**: 528-534 [PMID: 23348075 DOI: 10.1177/0363546512472979]

28 **Yoshimura I**, Kanazawa K, Hagio T, Minokawa S, Asano K, Naito M. The relationship between the lesion-to-ankle articular length ratio and clinical outcomes after bone marrow stimulation for small osteochondral lesions of the talus. *J Orthop Sci* 2015; **20**: 507-512 [PMID: 25687655 DOI: 10.1007/s00776-015-0699-3]

29 **Becher C**, Zühlke D, Plaas C, Ewig M, Calliess T, Stukenborg-Colsman C, Thermann H. T2-mapping at 3 T after microfracture in the treatment of osteochondral defects of the talus at an average follow-up of 8 years. *Knee Surg Sports Traumatol Arthrosc* 2015; **23**: 2406-2412 [PMID: 24562698 DOI: 10.1007/s00167-014-2913-9]

30 **Kim YS**, Lee HJ, Choi YJ, Kim YI, Koh YG. Does an injection of a stromal vascular fraction containing adipose-derived mesenchymal stem cells influence the outcomes of marrow stimulation in osteochondral lesions of the talus? A clinical and magnetic resonance imaging study. *Am J Sports Med* 2014; **42**: 2424-2434 [PMID: 25106781 DOI: 10.1177/0363546514541778]

31 **Li S**, Li H, Liu Y, Qu F, Wang J, Liu C. Clinical outcomes of early weight-bearing after arthroscopic microfracture during the treatment of osteochondral lesions of the talus. *Chin Med J* (Engl) 2014; **127**: 2470-2474 [PMID: 24985585]

32 **Choi JI**, Lee KB. Comparison of clinical outcomes between arthroscopic subchondral drilling and microfracture for osteochondral lesions of the talus. *Knee Surg Sports Traumatol Arthrosc* 2016; **24**: 2140-2147 [PMID: 25649727 DOI: 10.1007/s00167-015-3511-1]

33 **Grant HM**, Tjoumakaris FP, Maltenfort MG, Freedman KB. Levels of Evidence in the Clinical Sports Medicine Literature: Are We Getting Better Over Time? *Am J Sports Med* 2014; **42**: 1738-1742 [PMID: 24758781 DOI: 10.1177/0363546514530863]

34 **Sackett DL**, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. *BMJ* 1996; **312**: 71-72 [PMID: 8555924]

35 **Moher D**, Cook DJ, Jadad AR, Tugwell P, Moher M, Jones A, Pham B, Klassen TP. Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. *Health Technol Assess* 1999; **3**: i-iv, 1-98 [PMID: 10374081]

36 **Hannon CP**, Murawski CD, Fansa AM, Smyth NA, Do H, Kennedy JG. Microfracture for osteochondral lesions of the talus: a systematic review of reporting of outcome data. *Am J Sports Med* 2013; **41**: 689-695 [PMID: 22967827 DOI: 10.1177/0363546512458218]

37 **Chess LE**, Gagnier J. Risk of bias of randomized controlled trials published in orthopaedic journals. *BMC Med Res Methodol* 2013; **13**: 76 [PMID: 23758875 DOI: 10.1186/1471-2288-13-76]

38 **Tallon C**, Coleman BD, Khan KM, Maffulli N. Outcome of surgery for chronic Achilles tendinopathy. A critical review. *Am J Sports Med* 2001; **29**: 315-320 [PMID: 11394602]

39 **Gougoulias N**, Khanna A, McBride DJ, Maffulli N. Management of calcaneal fractures: systematic review of randomized trials. *Br Med Bull* 2009; **92**: 153-167 [PMID: 19734165 DOI: 10.1093/bmb/ldp030]

40 **Wang J**, Hua Y, Chen S, Li H, Zhang J, Li Y. Arthroscopic repair of lateral ankle ligament complex by suture anchor. *Arthroscopy* 2014; **30**: 766-773 [PMID: 24680321 DOI: 10.1016/j.arthro.2014.02.023]

41 **Moksnes H**, Engebretsen L, Risberg MA. The current evidence for treatment of ACL injuries in children is low: a systematic review. *J Bone Joint Surg Am* 2012; **94**: 1112-1119 [PMID: 22717830 DOI: 10.2106/JBJS.K.00960]

42 **Papalia R**, Franceschi F, Zampogna B, Tecame A, Maffulli N, Denaro V. Surgical management of partial tears of the anterior cruciate ligament. *Knee Surg Sports Traumatol Arthrosc* 2014; **22**: 154-165 [PMID: 23263259 DOI: 10.1007/s00167-012-2339-1]

43 **Pinski JM**, Boakye LA, Murawski CD, Hannon CP, Ross KA, Kennedy JG. Low Level of Evidence and Methodologic Quality of Clinical Outcome Studies on Cartilage Repair of the Ankle. *Arthroscopy* 2016; **32**: 214-22.e1 [PMID: 26372522 DOI: 10.1016/j.arthro.2015.06.050]

44 **Steinwachs MR**, Guggi T, Kreuz PC. Marrow stimulation techniques. *Injury* 2008; **39** Suppl 1: S26-S31 [PMID: 18313469 DOI: 10.1016/j.injury.2008.01.042]

45 **Goldberg A**, Mitchell K, Soans J, Kim L, Zaidi R. The use of mesenchymal stem cells for cartilage repair and regeneration: a systematic review. *J Orthop Surg Res* 2017; **12**: 39 [PMID: 28279182 DOI: 10.1186/s13018-017-0534-y]

**P-Reviewer:** Castagnini F, Xavier-Elsas P **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Orthopedics

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Figure 1 PRISMA study selection flow diagram.**



**Table 1 Modified Coleman Methodology Score[6]**

|  |  |  |
| --- | --- | --- |
| Section  | No. or factor | Score |
| Part A: Only one score to be given for each section |
| 1 Study size - number of patients |
|  | > 60 | 10 |
|  | 41-60 | 7 |
|  | 20-40 | 4 |
|  | < 20, not stated | 0 |
| 2 Mean follow up (mo) |
|  | > 24 | 5 |
|  | 12-24 | 2 |
|  | < 12, not stated or unclear | 0 |
| 3 Number of different surgical procedures included in each reported outcome. More than one surgical technique may be assessed but separate outcomes should be reported |
|  | One surgical procedure | 10 |
|  | More than one surgical procedure, but > 90% of subjects undergoing the one procedure | 7 |
|  | Not stated, unclear, or < 90% of subjects undergoing the one procedure | 0 |
| 4 Type of study |
|  | Randomized controlled trial | 15 |
|  | Prospective cohort study | 10 |
|  | Retrospective cohort study | 0 |
| 5 Diagnostic certainty (MRI) |
|  | In all | 5 |
|  | In > 80% | 3 |
|  | In < 80% | 0 |
| 6 Description of surgical procedure given |
|  | Adequate (technique stated and necessary details of that type of procedure given)  | 5 |
|  | Fair (technique only stated without elaboration) | 3 |
|  | Inadequate, not stated, or unclear  | 0 |
| 7 Description of postoperative rehabilitation |
|  | Well described (ROM, WB and sport) | 10 |
|  | Not adequately described (2 items between ROM and WB and sport) | 5 |
|  | Protocol not reported | 0 |
| Part B: Scores may be given for each option in each of the three sections if applicable |
| 1 Outcome criteria  |
|  | Outcome measures clearly defined | 2 |
|  | Timing of outcome assessment clearly stated (*e.g.*, at best outcome after surgery or follow-up) | 2 |
|  | Objective, subjective and imaging criteria | 6 |
|  | 2 items between objective, subjective and imaging criteria | 4 |
|  | Objective or subjective or radiological criteria | 2 |
| 2 Procedure for assessing outcomes  |
|  | Subjects recruited (results not taken from surgeons files) | 5 |
|  | Investigator independent of surgeon | 4 |
|  | Written assessment | 3 |
|  | Completion of assessment by subjects themselves with minimal investigator assistance  | 3 |
| 3 Description of subject selection process |
|  | Selection criteria reported and unbiased | 5 |
|  | Recruitment rate reported |  |
|  | > 80% or | 5 |
|  | < 80% | 3 |
|  | Eligible subjects not included in the study satisfactorily accounted for, or 100% recruitment | 5 |

MRI: Magnetic resonance imaging; ROM: Range of motion; WB: Weight bearing.

|  |
| --- |
| **Table 2 Studies included and demographic datas** |
| **Ref.** | **Year**  | **No. of ankles** | **No. of males** | **No. of females** | **Follow -up (mo)** | **Lesion area (mm2)** | **Lesion diameter (mm)** | **Prognostic factors** | **LOE** | **MCMS (points)** |
|  [[23]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_23) | 2013 | 50 | 20 | 30 | 35.5 | 61.7 | 8.8 | Lesion size | III | 58 |
|  [[29]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_29) | 2015 | 15 | 7 | 8 | 94.8 | 87 |  | Lesion size | IV | 50 |
|  [[5]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_5) | 2009 | 120 | 80 | 37 | 35.6 | 111.7 | 11.4 | Lesion size | III | 56 |
|  [[3]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_3) | 2013 | 399 |  |  | 74 | 111.3 |  | Lesion size, contained | III | 61 |
|  [[32]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_32) | 2015 | 90 | 68 | 22 | 38.3 | 100 |  | Lesion size | III | 67 |
|  [[24]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_24) | 2013 | 298 | 184 | 114 | 52 | 98.5 |  | Lesion size | III | 57 |
|  [[19]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_19) | 2012 | 173 | 121 | 52 | 70.3 | 95.4 |  | Lesion size | III | 54 |
|  [[4]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_4) | 2008 | 105 | 73 | 32 | 31.6 |  | 8.84 | Lesion size | IV | 57 |
|  [[16]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_16) | 2000 | 17 | 13 | 4 | 84 | 85.2 |  | Lesion size | III | 33 |
|  [[13]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_12) | 2006 | 10 | 6 | 4 | 53 | 450 |  | Lesion size | II | 61 |
|  [[18]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_18) | 2011 | 22 | 16 | 6 | 32 | 76 |  | Lesion size | IV | 45 |
|  [[30]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_30) | 2014 | 50 | 28 | 22 | 27.1 |  |  | Lesion size | III | 69 |
|  [[20]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_20) | 2012 | 22 | 12 | 10 | 24 |  |  | Lesion size | IV | 56 |
|  [[21]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_21) | 2012 | 81 | 64 | 17 | 37.4 | 100 |  | Lesion size | III | 89 |
|  [[17]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_17) | 2010 | 35 | 27 | 8 | 33 | 90 |  | Lesion size | IV | 50 |
|  [[31]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_31) | 2014 | 58 | 37 | 21 | 35 | 124 |  | Lesion size | IV | 65 |
|  [[25]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_25) | 2013 | 50 | 30 | 20 | 141 |  | 8.8 | Lesion size | IV | 62 |
|  [[26]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_26) | 2013 | 38 | 23 | 15 | 52.8 | 100 |  | Lesion size | IV | 52 |
|  [[27]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_27) | 2013 | 50 | 22 | 28 | 36.3 | 62 |  | Lesion size | IV | 66 |
|  [[28]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_28) | 2015 | 41 | 17 | 24 | 42.5 | 67 |  | Lesion size | IV | 56 |
|  [[22]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_22) | 2012 | 25 | 19 | 5 | 32 | 110 |  | Lesion size | IV | 48 |
|  [[7]](file:///J%3A%5C%E8%AB%96%E6%96%87%E3%83%AF%E3%83%BC%E3%82%AF%5CLaura%5CJISAKOS%20intructions%5Csubmission%5Cfinal%5CTable%202.xlsx#RANGE!_ENREF_6) | 2011 | 130 | 64 | 66 | 37.2 | 84 |   | Lesion size, contained | IV | 50 |

LOE: Level of evidence; MCMS: Modfied Coleman Methodology Score.

**Table 3 Outcome of modified Coleman methodology scores**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Part A** | **Part B** | **Total** |
| **Ref.** | **1 Study size - number of patients**  | **2 Mean follow-up (mo)**  | **3 No. of different surgical procedures included in each reported outcome** | **4 Type of study**  | **5 Diagnostic certainty (MRI)** | **6 Description of surgical procedure given** | **7 Description of postoperative rehabilitation** | **1 Outcome criteria**  | **2 Procedure for assessing outcomes**  | **3 Description of subject selection process** |  |
| [23] | 7 | 5 | 10 | 0 | 5 | 3 | 10 | 8 | 5 | 5 | 58 |
| [29] | 0 | 5 | 10 | 0 | 0 | 5 | 10 | 10 | 5 | 5 | 50 |
| [5] | 10 | 5 | 10 | 0 | 5 | 5 | 10 | 8 | 5 | 0 | 58 |
|  [3] | 10 | 5 | 10 | 0 | 5 | 5 | 10 | 8 | 8 | 0 | 61 |
| [32] | 10 | 5 | 10 | 0 | 5 | 5 | 5 | 6 | 3 | 8 | 57 |
| [24] | 10 | 5 | 10 | 0 | 5 | 5 | 10 | 10 | 9 | 3 | 67 |
|  [18] | 10 | 5 | 10 | 0 | 5 | 5 | 10 | 8 | 3 | 0 | 56 |
|  [4] | 10 | 5 | 10 | 0 | 5 | 3 | 10 | 6 | 8 | 0 | 57 |
| [16] | 4 | 5 | 10 | 0 | 0 | 3 | 0 | 8 | 5 | 3 | 38 |
| [13] | 4 | 5 | 0 | 10 | 5 | 5 | 10 | 10 | 9 | 3 | 61 |
|  [18] | 4 | 5 | 10 | 0 | 5 | 5 | 5 | 6 | 5 | 0 | 45 |
| [30] | 7 | 5 | 10 | 0 | 5 | 5 | 10 | 10 | 9 | 8 | 69 |
|  [20] | 4 | 2 | 10 | 0 | 5 | 3 | 5 | 10 | 9 | 8 | 56 |
| [21] | 10 | 5 | 10 | 15 | 5 | 5 | 10 | 10 | 9 | 10 | 89 |
| [17] | 4 | 5 | 10 | 0 | 5 | 5 | 5 | 8 | 5 | 3 | 50 |
| [31] | 7 | 5 | 10 | 0 | 5 | 5 | 10 | 10 | 5 | 8 | 65 |
| [25] | 7 | 5 | 10 | 0 | 0 | 3 | 5 | 10 | 12 | 5 | 57 |
| [26] | 4 | 5 | 10 | 0 | 5 | 3 | 10 | 10 | 5 | 0 | 52 |
| [27] | 7 | 5 | 10 | 0 | 5 | 3 | 10 | 8 | 8 | 10 | 66 |
|  [28] | 7 | 5 | 10 | 0 | 5 | 3 | 10 | 8 | 5 | 3 | 56 |
| [22] | 4 | 2 | 10 | 0 | 5 | 5 | 5 | 8 | 9 | 0 | 48 |
| [7] | 10 | 5 | 0 | 0 | 5 | 0 | 10 | 10 | 5 | 5 | 50 |
| mean | 6.8 | 4.7 | 9.1 | 1.1 | 4.3 | 4 | 8.2 | 8.6 | 6.6 | 4 | 57.5 |
| SD | 3 | 0.9 | 2.9 | 3.8 | 1.8 | 1.3 | 2.9 | 1.4 | 2.4 | 3.5 | 10.2 |

MRI: Magnetic resonance imaging.